echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Endocrine System > JAHA: Impact of endocrine therapy on cardiovascular disease and type 2 diabetes in breast cancer survivors

    JAHA: Impact of endocrine therapy on cardiovascular disease and type 2 diabetes in breast cancer survivors

    • Last Update: 2022-10-25
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Breast cancer is the most common cancer in women, and its prevalence is steadily increasing
    worldwide.
    The incidence of breast cancer in South Korea continues to rise
    in all ages.
    The main characteristics of breast cancer in Korea are that the incidence rate is higher among young women aged 40~49, the proportion of premenopausal women increases, and the survival rate is higher than that of other countries
    .
    Improved cancer screening and advanced cancer treatment will further increase the number of
    breast cancer survivors.
    While endocrine therapy is an effective treatment for breast cancer, its anti-estrogenic effects have been linked to
    an increased risk of cardiovascular disease and type 2 diabetes.

    Recently, JAHA, an authoritative journal in the field of cardiovascular diseases, published a research article that aims to investigate the relationship between endocrine therapy and cardiovascular disease and type 2 diabetes risk in breast cancer survivors in Korea, taking into account the differences
    in different age groups.

    A total of 133171 breast cancer patients over the age of 20 were included in the Korean
    National Health Insurance database.
    Endocrine therapy is considered a time-varying exposure, and patients are divided into no use, selective estrogen receptor modulators, aromatase inhibitors, and both
    .
    Time-dependent Cox regression models were used to estimate hazard ratios (HRs) and 95% CIs
    .
    Age at diagnosis, socioeconomic status, histologic type, other treatments, and comorbidities were adjusted
    in the model.

    Patients with selective estrogen receptor modulators had a higher risk of stroke (HR 1.
    20 [95% CI 1.
    04 to 1.
    40]) and venous thromboembolism (HR 1.
    47 [95% CI 1.
    13 to 1.
    90]) compared with those who did not use estrogen receptor modulators, while those with aromatase inhibitors had a higher risk of coronary heart disease (HR 1.
    22 [95% CI 1.
    06 to 1.
    41]).

    。 The risk of type 2 diabetes was associated with
    users of selective estrogen receptor modulators (HR 1.
    13 [95% CI 1.
    05 to 1.
    21]), aromatase inhibitor users (HR 1.
    14 [95% CI 1.
    05 to 1.
    23]), and both users (HR 1.
    24 [95% CI 1.
    10 to 1.
    39]).
    In particular, in young or premenopausal patients, the risk of cardiovascular disease is higher
    .

    It can be seen that among breast cancer survivors in Korea, endocrine therapy is associated
    with a high risk of cardiovascular disease and type 2 diabetes.
    In young and elderly patients, cancer comorbidities
    following endocrine therapy need to be monitored.

    Original source:

    Ji‐Eun Kim,et al.
    Effects of Endocrine Therapy on Cardiovascular Diseases and Type 2 Diabetes Among Breast Cancer Survivors: The National Health Insurance Service Database of Korea.
    JAHA.
    2022.
    https:// www.
    ahajournals.
    org/doi/10.
    1161/JAHA.
    122.
    026743

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.